2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkers
2021
Neurological Side Effects of Psychotropic Medications
Malik S, Sahl R, Elzamzamy K, Nakhla M, Azeem M. Neurological Side Effects of Psychotropic Medications. Psychiatric Annals 2021, 51: 402-409. DOI: 10.3928/00485713-20210802-01.Peer-Reviewed Original ResearchNeurological side effectsSide effectsPotential side effectsPotential neurological side effectsExtrapyramidal side effectsMechanism of actionAcute dystoniaPsychotropic medicationsPsychotropic agentsMotor ticsSignificant negative factorCliniciansAkathisiaTolerabilityDeliriumMedicationsMyoclonusDystoniaParkinsonismSeizuresDiagnosis
2020
Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”
Garakani A. Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”. Journal Of Psychiatric Practice 2020, 26: 510-517. PMID: 33275389, DOI: 10.1097/pra.0000000000000507.Commentaries, Editorials and LettersConceptsPrimary psychiatric disordersYears of ageWilson's diseasePsychiatric disordersNew onsetDiagnostic workupAcute cognitive declineFormal psychiatric historyCommon clinical manifestationsNeurological side effectsFurther diagnostic workupLow serum ceruloplasminMagnetic resonance imagingSecondary maniaAtypical presentationClinical manifestationsHepatic abnormalitiesPsychiatric providersPatient presentationMetabolism disordersBrain abnormalitiesPsychiatric symptomsTreatment considerationsCorrect diagnosisPsychiatric history
2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove outcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed models
2009
A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors
Deshpande H, Gettinger S, Rowen E, Abu-Khalaf M, Clarke J, Burns A, Kelly W. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2009, 27: e13501-e13501. DOI: 10.1200/jco.2009.27.15_suppl.e13501.Peer-Reviewed Original ResearchNanoparticle albumin-bound paclitaxelAlbumin-bound paclitaxelCohort 2Cohort 3Cohort 1Platinum agentsSolid tumorsDay 14Common severe adverse eventsGrade 3 anemiaMedian age 51Grade 4 neutropeniaStandard chemotherapy regimenAdvanced solid tumorsPhase 2 studySevere adverse eventsNeurological side effectsCycle 1Stable diseaseChemotherapy regimenDay 1 treatmentAdvanced malignanciesAdverse eventsPartial responseProgressive disease
1988
Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa
BUNNEY B. Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa. Annals Of The New York Academy Of Sciences 1988, 537: 77-85. PMID: 2904786, DOI: 10.1111/j.1749-6632.1988.tb42097.x.Peer-Reviewed Original ResearchConceptsAD administrationDA releaseDA cell activityChronic neuroleptic treatmentMidbrain DA neuronsRelease of DAEffects of AcuteNeurological side effectsDA neuronsNeuroleptic treatmentAcute effectsNerve terminalsSpontaneous activitySide effectsCell activityMarked increaseAdministrationProjection areaPrimary effectReleaseAcuteMarked effectNeuronsActivityBiochemical techniques
1979
EFFECTS OF CHRONIC HALOPERIDOL TREATMENT ON NIGRAL DOPAMINERGIC CELL ACTIVITY
Bunney B, Grace A. EFFECTS OF CHRONIC HALOPERIDOL TREATMENT ON NIGRAL DOPAMINERGIC CELL ACTIVITY. 1979, 666-668. DOI: 10.1016/b978-1-4832-8363-0.50202-0.Peer-Reviewed Original ResearchActive DA cellsChronic haloperidol treatmentDA cellsExtracellular single-unit recording techniquesRat nigral dopaminergic neuronsSingle-unit recording techniquesNigral dopaminergic neuronsNeurological side effectsEffects of chronicDepolarization inactivationHaloperidol treatmentDopaminergic neuronsExcitatory inputsSide effectsCell activityRecording techniquesPossible new mechanismSubsequent studiesTreatmentCellsAnimalsNigralChronicNeurons
1978
Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity
Bunney B, Grace A. Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sciences 1978, 23: 1715-1727. PMID: 31529, DOI: 10.1016/0024-3205(78)90471-x.Peer-Reviewed Original ResearchConceptsChronic haloperidol treatmentDA cellsHaloperidol treatmentControl animalsCell activityExtracellular single-unit recordingsDopaminergic cell activityDopaminergic neuronal activityNigral DA cellsNeurological side effectsDopamine cell activitySingle-unit recordingsFeedback pathwaysComparison of effectsDA neuronsTime-dependent mannerMicroiontophoretic techniquesClinical effectsKainic acidAntipsychotic drugsDepolarization blockCaudate nucleusNeuronal activitySide effectsUnit recordings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply